X

Trial Profile

A MULTINATIONAL, MULTICENTER STUDY TO ASSESS THE EFFECTS OF ORAL SILDENAFIL ON MORTALITY IN ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH)

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sildenafil (Primary)
Indications Pulmonary arterial hypertension
Focus Therapeutic Use
Acronyms AFFILIATE
Sponsors Pfizer

Most Recent Events

24 Aug 2022 This trial has been completed in Croatia, according to European Clinical Trials Database record. (26 Feb 2021)
15 Apr 2022 Status changed from completed to discontinued.
01 Apr 2021 This trial has been completed in Czechia (Global end date: 2021-03-26),according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com